Upsher Smith Laboratories Inc - Company & Market Research Reports

Upsher-Smith Laboratories is a family-owned, privately-held pharmaceutical company, based in the Midwest of the United States. It specializes in therapies and solutions for people living with central nervous system (CNS) conditions, such as seizure disorders. It also offers drugs for dermatology and heart health, and for conditions including epilepsy, spasticity, schizophrenia, bipolar disorder, hypertension, and bladder instability. Founded in 1919, the company is headquartered in Maple Grove, Minnesota.

Transdermal Drug Delivery Market: By Technology; By Application, Pain Management, Cardiovascular, Others & By Region - Forecast 2017-2022 - Product Thumbnail Image

Transdermal Drug Delivery Market: By Technology; By Application, Pain Management, Cardiovascular, Others & By Region - Forecast 2017-2022

  • Report
  • 169 Pages
From
Peptide Therapeutics in Metabolic Disorders, 2016 - 2025 - Product Thumbnail Image

Peptide Therapeutics in Metabolic Disorders, 2016 - 2025

  • Report
  • 436 Pages
From
CNS Therapeutics - Global Strategic Business Report - Product Thumbnail Image

CNS Therapeutics - Global Strategic Business Report

  • Report
  • 611 Pages
From
Global Postmenopausal Osteoporosis Drugs Market 2016-2020 - Product Thumbnail Image

Global Postmenopausal Osteoporosis Drugs Market 2016-2020

  • Report
  • 60 Pages
From
Anti-Epileptic Drugs: Global Markets to 2022 - Product Thumbnail Image

Anti-Epileptic Drugs: Global Markets to 2022

  • Report
  • 161 Pages
From
Parkinson's Disease Treatment Market by Drug Class (Carbidopa/Levodopa, Dopamine Receptor Agonists, MAO-Inhibitors), Distribution Channel (Hospital, Online, Retail Pharmacies), Patient Care Setting (Hospitals, Clinics) - Global Forecast to 2022 - Product Thumbnail Image

Parkinson's Disease Treatment Market by Drug Class (Carbidopa/Levodopa, Dopamine Receptor Agonists, MAO-Inhibitors), Distribution Channel (Hospital, Online, Retail Pharmacies), Patient Care Setting (Hospitals, Clinics) - Global Forecast to 2022

  • Report
  • 115 Pages
From
Drug Delivery in Central Nervous System Diseases - Technologies, Markets and Companies - Product Thumbnail Image

Drug Delivery in Central Nervous System Diseases - Technologies, Markets and Companies

  • Report
  • 385 Pages
From
Intranasal Drug Delivery - Global Strategic Business Report - Product Thumbnail Image

Intranasal Drug Delivery - Global Strategic Business Report

  • Report
  • 239 Pages
From
Qudexy XR 2016 U.S Promotional Report - Product Thumbnail Image

Qudexy XR 2016 U.S Promotional Report

  • Report
  • 21 Pages
From
Antiepileptic Drugs Market: By Type; By Geography - Study With Forecast 2016-2021 - Product Thumbnail Image

Antiepileptic Drugs Market: By Type; By Geography - Study With Forecast 2016-2021

  • Report
  • 135 Pages
From
Global Epilepsy Drugs Market 2016-2020 - Product Thumbnail Image

Global Epilepsy Drugs Market 2016-2020

  • Report
  • 87 Pages
From
Epilepsy- Competitive Landscape, Market and Pipeline Analysis, 2018 - Product Thumbnail Image

Epilepsy- Competitive Landscape, Market and Pipeline Analysis, 2018

  • Drug Pipelines
  • 147 Pages
From
Epilepsy - Pipeline Review, H1 2018 - Product Thumbnail Image

Epilepsy - Pipeline Review, H1 2018

  • Report
  • 418 Pages
From
PharmaPoint: Epilepsy - Global Drug Forecast and Market Analysis to 2026 - Product Thumbnail Image

PharmaPoint: Epilepsy - Global Drug Forecast and Market Analysis to 2026

  • Report
  • 299 Pages
From
Seizures - Pipeline Review, H2 2016 - Product Thumbnail Image

Seizures - Pipeline Review, H2 2016

  • Report
  • 214 Pages
From
Kainate Receptor Antagonist -Pipeline Insight, 2018 - Product Thumbnail Image

Kainate Receptor Antagonist -Pipeline Insight, 2018

  • Drug Pipelines
  • 60 Pages
From
AMPA Receptor Antagonist -Pipeline Insight, 2018 - Product Thumbnail Image

AMPA Receptor Antagonist -Pipeline Insight, 2018

  • Drug Pipelines
  • 60 Pages
From
C-X-C Chemokine Receptor Type 4 (Fusin or Leukocyte-Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide-Associated Protein 3 or Stromal Cell-Derived Factor 1 Receptor or CD184 or CXCR4) - Pipeline Review, H1 2016 - Product Thumbnail Image

C-X-C Chemokine Receptor Type 4 (Fusin or Leukocyte-Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide-Associated Protein 3 or Stromal Cell-Derived Factor 1 Receptor or CD184 or CXCR4) - Pipeline Review, H1 2016

  • Report
  • 116 Pages
From
Oral Proteins and Peptides Market (2nd Edition), 2015 - 2025 - Product Thumbnail Image

Oral Proteins and Peptides Market (2nd Edition), 2015 - 2025

  • Report
  • 175 Pages
From
Dermatitis - Pipeline Review, H1 2015 - Product Thumbnail Image

Dermatitis - Pipeline Review, H1 2015

  • Report
  • 381 Pages
From
Loading Indicator
adroll